A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine
- 206 Downloads
Abstract
Aims
To compare the diurnal glycemic profiles obtained with basal insulin degludec (InsDeg) and basal insulin glargine (InsGla) in patients with type 1 diabetes using continuous glucose monitoring (CGM) in an outpatient setting.
Methods
Twenty Japanese patients with type 1 diabetes who were using once-daily InsGla before supper as part of their multiple daily insulin injections were consecutively recruited. CGM was initiated before supper on day 1, and InsGla was switched to InsDeg at the same dose on day 3. The average CGM glucose profile obtained on days 1 and 2 was compared with the corresponding profile for days 5 and 6. The bolus insulin regimen was not changed during the study period.
Results
CGM glucose was significantly higher (p < 0.05) from 19:30 to 22:30 and significantly lower (p < 0.05) from 6:30 to 8:00 with basal InsDeg than with basal InsGla. The duration of hypoglycemia (<70 mg/dl) was the same regardless of whether basal InsDeg or basal InsGla was used.
Conclusions
The peak in the action profile of InsDeg lasts longer and is possibly stronger than that of InsGla.
Keywords
Insulin degludec Insulin glargine Type 1 diabetes Continuous glucose monitoring (CGM)Notes
Acknowledgments
We acknowledge Kazumi Hata for excellent secretarial work, Yuko Kanbara for data collection, and Toshihito Furukawa for statistical analysis.
Compliance with ethical standards
Conflict of interest
MM received honoraria from Sanofi, which markets insulin glargine.
Human rights and informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients before they were included in the study.
References
- 1.Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Heller S, Buse J, Fisher M, BEGIN Basal-Bolus Type 1 Trial Investigators, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97.CrossRefPubMedGoogle Scholar
- 3.Zinman B. Newer insulin analogs: advances in basal insulin replacement. Diabetes Obes Metab. 2013;15(Suppl 1):6–10.CrossRefPubMedGoogle Scholar
- 4.Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447–52.CrossRefPubMedGoogle Scholar
- 5.Atkin S, Javed Z, Fulcher G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis. 2015;6:375–88.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944–50.Google Scholar
- 7.Kuroda A, Kaneto H, Yasuda T, et al. Basal insulin requirement is ~30 % of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care. 2011;34:1089–90.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669–74.CrossRefPubMedPubMedCentralGoogle Scholar